You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
大和:首予維亞生物(1873.HK)10.4港元目標價 評級買入
格隆匯 11-09 16:14

大和發表研究報告指,維亞生物(1873.HK)早前收購小分子新藥研發合約研究機構,正式進軍CDMO(合同開發及製造組織)範疇。大和表示,該收購有助提升集團研發能力,擴大全球生物科技及製藥客户基礎,首予維亞生物目標價10.4港元,投資評級買入。

該行又指,維亞生物作為一家業務模式較為獨特的早期新藥發現技術服務平台,其收入由服務換現金(CFS)業務和服務換股權(EFS)業務雙輪驅動。在CFS業務模式下,集團能為大量初創企業服務,而EFS則有望獲得高投資回報,從而擴大其CFS覆蓋範圍,從而帶動集團業務增長。

該行預計CDMO業務令集團收入由2019年的3.23億元人民幣,增加到2021年的27.18億元人民幣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account